RVX-208 is a selective antagonist of BET bromodomains, binding with 10-100-fold higher affinity for BD2 (IC50 = 0.04-0.28 µM) over BD1 (IC50 = 1.8-3.1 µM). RVX-208 causes the selective release of BET proteins from chromatin in cells. It interferes with the BET protein BRD4, resulting in an increased expression of apolipoprotein (Apo) A1 in cells, mice, monkeys, and humans. RVX-208 also reduces atherosclerosis in hyperlipidemic ApoE-deficient mice.

Shipping & Handling

Shipped In

Room Temperature in continental US; may vary elsewhere

Safety & Storage

Storage Temperature

-20°C

Safety Statement

WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Regulatory & Compliance

Technical Documents

Datasheet (1)

HtJEb16424.pdf

MSDS (1)

ZWvoz16424m.pdf

Questions & Answers (0)

Citations (0)

Shipping & Handling

Shipped In

Room Temperature in continental US; may vary elsewhere

Safety & Storage

Storage Temperature

-20°C

Safety Statement

WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Regulatory & Compliance

We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.

Join BETA

Join Our List

Subscribe to the Scoop blog and get the latest updates on life in the lab.